News
Archive
Emporos and InterLink AI Partner, develop only POS-Integrated lighted will-call solution
Phase Four partners with Redwire to expand space propulsion offerings and deliver Hall Effect Thrusters
Ventyx Biosciences announces positive preclinical data for CNS-penetrant NLRP3 inhibitor VTX3232 demonstrating reversal of obesity and improvements in cardiometabolic and inflammatory markers
Resolve Therapeutics publishes results of RSLV-132 Phase 2 long COVID study
Finally, Graphene electronic devices available for all
DARPA awards Phase Four $14.9M contract to develop Air Breathing Electric Propulsion for Very Low Earth Orbit operations
Back To News![Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial](https://www.newscienceventures.com/wp-content/uploads/2020/11/vt98.jpg)
May 11, 2021
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.